Axovant Gene Therapies Announces Name Change to Sio Gene Therapies
10 Novembro 2020 - 9:00AM
Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage gene
therapy company developing innovative gene therapies for
neurodegenerative diseases, today announced it will change its name
to
Sio Gene Therapies, Inc., effective November
13, 2020. In connection with the name change, the company’s ticker
will change to “SIOX” and will be effective at market open on
November 13, 2020, along with the company’s new corporate website
at www.siogtx.com. The former ticker “AXGT” will remain effective
through market close on November 12, 2020. SIOX will ring the
Nasdaq Closing Bell at 4:00 pm ET on Monday, November 16, 2020.
“Since its inception, Axovant has undergone transformations in
its vision, portfolio strategy, ownership, and corporate
structure,” said Pavan Cheruvu, M.D., Chief Executive Officer at
Axovant. “From our management team and Board of Directors to our
gene therapy pipeline and R&D capabilities, the Axovant Gene
Therapies of today is very different from the small molecule
development company it was just a few years ago. As a newly
independent company, we are proud to share our identity, Sio Gene
Therapies, which reflects our scientific vision to develop
disease-modifying and curative genetic medicines. ‘Sio’ represents
a new beginning for the company, our shareholders, and most
importantly, the patients we serve.”
Dr. Cheruvu continued, “Our company develops genetic medicines
for devastating disorders – ranging from our potentially curative
AAV-based pipeline for monogenic pediatric diseases, in which young
children can expect to live only a few years, to AXO-Lenti-PD for
Parkinson’s disease, a condition that affects many millions of
patients globally and where gene therapy may have the ability to
slow progressive worsening in disability and quality of life. As we
write the first chapter of Sio’s story, we look forward to sharing
additional portfolio updates as we deliver on our goal of
liberating patients from debilitating diseases through the
transformational power of gene therapy.”
In conjunction with the corporate rebrand, the company has
established a majority independent Board of Directors and is in the
process of its redomiciliation from a Bermuda to a Delaware
corporation (“the Redomiciliation”).
No action is required by stockholders in connection with the
corporate name change and Redomiciliation. The Company’s common
stock has been assigned a new CUSIP number of 829399 104. The
number of outstanding shares of the Company’s common stock is also
not affected. In connection with the name change and
Redomiciliation, the Company expects to make additional ordinary
course filings with the U.S. Securities and Exchange Commission in
connection with planned effectiveness of its S-4 Registration
Statement related to the Redomiciliation and updating of its
existing S-3 shelf registration statement (and related ATM program)
and S-8 equity plan registration statement to reflect its new
corporate name and jurisdiction of incorporation.
About Axovant
Axovant Gene Therapies is a clinical-stage gene therapy company
focused on developing a pipeline of innovative product candidates
for debilitating neurodegenerative diseases. Our current pipeline
of gene therapy candidates targets GM1 gangliosidosis, GM2
gangliosidosis (also known as Tay-Sachs disease and Sandhoff
disease), and Parkinson’s disease. Axovant is focused on
accelerating product candidates into and through clinical trials
with a team of experts in gene therapy development and through
external partnerships with leading gene therapy organizations. For
more information, visit www.axovant.com.
Forward-Looking Statements
This press release contains forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
The use of words such as "will," "expect," "believe," "estimate,"
and other similar expressions are intended to identify
forward-looking statements. For example, all statements Axovant
makes regarding its corporate rebrand, its product development
plans and expectations, its stated goal of liberating patients from
debilitating diseases through gene therapy, and the expected timing
of its name change and new ticker on Nasdaq. All forward-looking
statements are based on estimates and assumptions by Axovant’s
management that, although Axovant believes to be reasonable, are
inherently uncertain. All forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ
materially from those that Axovant expected. Such risks and
uncertainties include, among others, the impact of the Covid-19
pandemic on our operations, the initiation and conduct of
preclinical studies and clinical trials; the availability of data
from clinical trials; the development of a suspension-based
manufacturing process; the scaling up of manufacturing, the
expectations for regulatory submissions and approvals; the
continued development of our gene therapy product candidates and
platforms; Axovant’s scientific approach and general development
progress; and the availability or commercial potential of Axovant’s
product candidates. These statements are also subject to a number
of material risks and uncertainties that are described in Axovant’s
most recent Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on August 11, 2020, as updated by its
subsequent filings with the Securities and Exchange Commission. Any
forward-looking statement speaks only as of the date on which it
was made. Axovant undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
Contacts:
Investors:Parag MeswaniAxovant Gene Therapies
Ltd.(212) 547-2523investors@axovant.com
Media:Josephine Belluardo, Ph.D.LifeSci
Communications646-751-4361jo@lifescicomms.commedia@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024